Value
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 1.6 |
| P/S | 6.6 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 3.9 |
| PEG | 10.0 |
| Analyst target | 7.5 |
- ▸Forward P/E: 30.6x
- ▸PEG: 0.00
ONC · Why this verdict
Why BeOne Medicines (ONC) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.6/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
BRUKINSA is BeOne Medicines' primary revenue driver, generating 36% year-over-year revenue growth that has established the company as a high-growth oncology franchise, but this single-product concentration means any clinical setback, generic threat, or pricing pressure on BRUKINSA would disproportionately impact the entire business. Bear case | BRUKINSA maintains revenue growth above 25% year-over-year for 2 consecutive quarters while pipeline products begin contributing measurable revenue, reducing single-product dependence. | →Stable |
| CounterBest-in-class hematology drugs routinely achieve multi-decade revenue growth during their market exclusivity periods, and BRUKINSA's clinical profile in chronic lymphocytic leukemia suggests durable demand even with emerging competition. | ||
BeOne Medicines is rated as having a wide economic moat and compounder quality with strong returns and growth, achieving a Piotroski F-Score of 9/9 and a Rule of 40 score of 51, which indicates the business is generating enough combined growth and profitability to justify a premium long-term valuation. Quality breakdown | Rule of 40 score stays above 45 over the next 4 reported quarters as revenue growth sustains and operating leverage expands margins. | →Stable |
| CounterA wide moat designation for a single-drug-dependent biotech reflects a current competitive position that can erode rapidly if competitive approvals arrive in the same indication, and the one miss in the last 4 quarters was a large -55% earnings miss that suggests execution variability. | ||
The stock is in a confirmed falling knife setup with RSI at 22, a death cross pattern (the 50-day moving average crossing below the 200-day moving average), below all moving averages, and falling on-balance volume — all of which represent a technically dangerous environment for new positions regardless of fundamental quality. Warnings | Momentum score recovers above 4.5 and the stock crosses back above its 200-day moving average within 3 months as RSI recovers from the oversold extreme below 30. | →Stable |
| CounterRSI at 22 represents extreme oversold conditions in a high-quality business that historically snap back, and the strong analyst consensus (54% upside) combined with positive news sentiment suggests the sell-off may be creating a high-quality entry opportunity for patient investors. | ||
BeOne beat earnings estimates in 3 of the last 4 quarters with extraordinary positive surprises of 224%, 27%, and 143% in three recent quarters, and average surprise across all 4 quarters was 84.8%, suggesting the business generates profits that dramatically exceed analyst expectations. Earnings | Earnings beat streak extends to at least 3 of the next 4 quarters with average positive surprise remaining above 20%. | →Stable |
| CounterThe one miss was -55.3%, and the extraordinary beat magnitudes reflect a lumpy revenue recognition pattern in a growing oncology business rather than consistent quarterly delivery — making the average surprise figure difficult to interpret as a reliable forward indicator. | ||
BRUKINSA is BeOne Medicines' primary revenue driver, generating 36% year-over-year revenue growth that has established the company as a high-growth oncology franchise, but this single-product concentration means any clinical setback, generic threat, or pricing pressure on BRUKINSA would disproportionately impact the entire business.
→StableBear case
- Expectation
- BRUKINSA maintains revenue growth above 25% year-over-year for 2 consecutive quarters while pipeline products begin contributing measurable revenue, reducing single-product dependence.
CounterBest-in-class hematology drugs routinely achieve multi-decade revenue growth during their market exclusivity periods, and BRUKINSA's clinical profile in chronic lymphocytic leukemia suggests durable demand even with emerging competition.
BeOne Medicines is rated as having a wide economic moat and compounder quality with strong returns and growth, achieving a Piotroski F-Score of 9/9 and a Rule of 40 score of 51, which indicates the business is generating enough combined growth and profitability to justify a premium long-term valuation.
→StableQuality breakdown
- Expectation
- Rule of 40 score stays above 45 over the next 4 reported quarters as revenue growth sustains and operating leverage expands margins.
CounterA wide moat designation for a single-drug-dependent biotech reflects a current competitive position that can erode rapidly if competitive approvals arrive in the same indication, and the one miss in the last 4 quarters was a large -55% earnings miss that suggests execution variability.
The stock is in a confirmed falling knife setup with RSI at 22, a death cross pattern (the 50-day moving average crossing below the 200-day moving average), below all moving averages, and falling on-balance volume — all of which represent a technically dangerous environment for new positions regardless of fundamental quality.
→StableWarnings
- Expectation
- Momentum score recovers above 4.5 and the stock crosses back above its 200-day moving average within 3 months as RSI recovers from the oversold extreme below 30.
CounterRSI at 22 represents extreme oversold conditions in a high-quality business that historically snap back, and the strong analyst consensus (54% upside) combined with positive news sentiment suggests the sell-off may be creating a high-quality entry opportunity for patient investors.
BeOne beat earnings estimates in 3 of the last 4 quarters with extraordinary positive surprises of 224%, 27%, and 143% in three recent quarters, and average surprise across all 4 quarters was 84.8%, suggesting the business generates profits that dramatically exceed analyst expectations.
→StableEarnings
- Expectation
- Earnings beat streak extends to at least 3 of the next 4 quarters with average positive surprise remaining above 20%.
CounterThe one miss was -55.3%, and the extraordinary beat magnitudes reflect a lumpy revenue recognition pattern in a growing oncology business rather than consistent quarterly delivery — making the average surprise figure difficult to interpret as a reliable forward indicator.
TrendMatrix Research · core thesis
Engine thesis — one sentence
BeOne Medicines combines 36% revenue growth, a Piotroski F-Score of 9/9, a wide economic moat, and a Rule of 40 score of 51 with strong analyst conviction (54% upside consensus), but the stock is in a confirmed falling knife pattern with RSI at 22, a death cross in place, and BRUKINSA product concentration risk from a single revenue driver.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 4.1 |
| ROA | 4.0 |
| Gross margin | 10.0 |
| Op margin | 6.6 |
| Net margin | 4.5 |
| Current ratio | 9.4 |
| FCF quality | 10.0 |
| Moat | 7.6 |
| Rule of 40 | 8.3 |
| Piotroski F | 10.0 |
- ▸Excellent cash conversion: 165% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
- ▸Rule of 40: 50 (pass)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 36% YoY
Momentum
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.2 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 4.9 |
- ▸Overbought bear rally (RSI 82)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -1.6%/30d — confirmed downtrend
Sentiment
8.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.0 |
| Analyst rating | 9.0 |
| Price target | 8.8 |
- ▸LLM news sentiment: +0.60 (n=3)
- ▸Analyst upside: 33%
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $7,682,513 (0.025% of mkt cap)
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.4 |
| quality rank | 7.3 |
| growth rank | 6.4 |
- ▸Superior ROE vs peers
Technical
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 1.1 |
| 52w position | 6.1 |
| gap | 4.0 |
Risk (lower is worse)
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.4 |
| days to cover | 7.5 |
| volatility | 5.0 |
| put call | 10.0 |
| implied vol | 4.6 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 8.3 |
- ▸Above max pain $230
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 7.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (7)
- MOMENTUM:6.6>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:EARNINGS:0.70
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.3<1.5@spot
Warning (1)
- DEATH_CROSS:momentum=6.6>=5.0 recovering
Reward-to-Risk
1.33
Upside
+19.9%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 82
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:6.6>=5.5. Top dim: Growth at 10.0; weakest: Technical at 2.8. No conviction either direction.
The strongest dimensions are Growth at 10.0, Sentiment at 8.6, and Quality at 7.5; the weakest are Technical at 2.8, Insider at 3.8, and Peer rank at 4.5. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 1.33 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Brukinsa Concentration Growth Engine
Trip ifBRUKINSA revenue growth falls below 15% year-over-year for 2 consecutive quarters, indicating a meaningful slowdown in the primary growth engine.
- P2Wide Moat Compounder Quality
Trip ifRule of 40 score falls below 35 for 2 consecutive reported periods, indicating the growth and profitability combination is deteriorating.
- P3Falling Knife Technical Setup
Trip ifStock price drops below $250, extending the technical breakdown rather than reversing from the current oversold level of RSI 22.
- P4Exceptional Earnings Beat Pattern
Trip ifEPS surprise falls below -30% for 2 of the next 4 quarters, indicating the extraordinary beat pattern has reversed into a persistent miss trend.